Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
21/05/2026 23:06
May 21 (Reuters) - Biogen BIIB.O and Denali Therapeutics DNLI.O said on Thursday they will discontinue development of their Parkinson's drug it failed to meet the main goal in a mid-to-late stage study. (Reporting by Sahil Pandey in Bengaluru; Editing by Shailesh Kuber) ((Sahil.Pandey@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout